Real-world study tracks duration of hormone therapy in older men with advanced prostate cancer
NCT ID NCT06072196
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 25 times
Summary
This study looked at insurance records of over 3,000 men aged 65+ with metastatic prostate cancer that still responds to hormone therapy. Researchers wanted to see how long patients stayed on newer hormone drugs like abiraterone, apalutamide, or enzalutamide as part of their usual care. The goal was to understand real-world treatment patterns, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer, Inc
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.